A San Francisco Bay Area biotech firm was cleared of any wrongdoing last week when a federal jury in Philadelphia rejected the claims of an ophthalmologist who alleged he was cheated out of his promised share of the profits from a new treatment for macular degeneration — the leading cause of blindness in people over the age of 60.
In the suit, plaintiff Kourosh A. Dastgheib claimed that he had provided “vitally important” research to Genentech Inc. that led to its development of the drug Lucentis, but that the company reneged on its promise to give him 1 percent of its gross revenues and professional recognition for his role in discovering the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]